BACKGROUND: Currently, advanced prostate cancer (CaP) is not curable. In this report hyperbaric oxygen (HBO) is examined as an adjuvant to chemotherapy and as a stand-alone treatment. MATERIALS AND METHODS: CaP cell monolayers grown under normoxic conditions were exposed to cisplatin, taxol or doxorubicin for 90 minutes under HBO (3.0 atmospheres, 100% O2) or normal pressure air. RESULTS: HBO reduced by 47% the concentration of doxorubicin required to produce a 20% reduction in cell numbers, but did not change the concentration required to produce a > 50% reduction. HBO increased the sensitivity of PC-3 cells to taxol at all concentrations, (mean 1.8%). Cisplatin chemosensitivity was not affected by HBO. HBO reduced the growth rate of DU-145 8.1% relative to control (p = 0.01), and PC-3 2.7% (p = 0.12). CONCLUSIONS: This study shows that HBO can decrease the rate of growth, and increase sensitivity to anticancer agents, however, the effects are cell line dependent.
BACKGROUND: Currently, advanced prostate cancer (CaP) is not curable. In this report hyperbaric oxygen (HBO) is examined as an adjuvant to chemotherapy and as a stand-alone treatment. MATERIALS AND METHODS: CaP cell monolayers grown under normoxic conditions were exposed to cisplatin, taxol or doxorubicin for 90 minutes under HBO (3.0 atmospheres, 100% O2) or normal pressure air. RESULTS: HBO reduced by 47% the concentration of doxorubicin required to produce a 20% reduction in cell numbers, but did not change the concentration required to produce a > 50% reduction. HBO increased the sensitivity of PC-3 cells to taxol at all concentrations, (mean 1.8%). Cisplatin chemosensitivity was not affected by HBO. HBO reduced the growth rate of DU-145 8.1% relative to control (p = 0.01), and PC-3 2.7% (p = 0.12). CONCLUSIONS: This study shows that HBO can decrease the rate of growth, and increase sensitivity to anticancer agents, however, the effects are cell line dependent.
Authors: Orhan Tezcan; Oguz Karahan; Mustafa Alan; Cenap Ekinci; Celal Yavuz; Sinan Demirtas; Aysun Ekinci; Ahmet Caliskan Journal: Acta Cardiol Sin Date: 2017-03 Impact factor: 2.672
Authors: Stella Sun; Derek Lee; Nikki P Lee; Jenny K S Pu; Stanley T S Wong; W M Lui; C F Fung; Gilberto K K Leung Journal: J Neurooncol Date: 2012-07-05 Impact factor: 4.130
Authors: Kristine Yttersian Sletta; Maria K Tveitarås; Ning Lu; Agnete S T Engelsen; Rolf K Reed; Annette Garmann-Johnsen; Linda Stuhr Journal: PLoS One Date: 2017-08-23 Impact factor: 3.240
Authors: Ingrid Moen; Karl J Tronstad; Odd Kolmannskog; Gerd S Salvesen; Rolf K Reed; Linda E B Stuhr Journal: BMC Cancer Date: 2009-12-17 Impact factor: 4.430
Authors: Bryan Oronsky; Jan Scicinski; Michelle M Kim; Pedro Cabrales; Michael E Salacz; Corey A Carter; Neil Oronsky; Harry Lybeck; Michelle Lybeck; Christopher Larson; Tony R Reid; Arnold Oronsky Journal: Biomolecules Date: 2016-07-04